Bright Minds Biosciences (DRUG) Projected to Post Quarterly Earnings on Monday

Bright Minds Biosciences (NASDAQ:DRUG) is expected to be posting its Q4 2025 results before the market opens on Monday, December 29th. Analysts expect Bright Minds Biosciences to post earnings of ($1.2050) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, December 23, 2025 at 7:00 AM ET.

Bright Minds Biosciences Stock Down 3.0%

DRUG opened at $82.12 on Friday. Bright Minds Biosciences has a 12 month low of $23.17 and a 12 month high of $97.75. The stock has a market cap of $639.71 million, a P/E ratio of -67.31 and a beta of -6.22. The company has a fifty day simple moving average of $68.37 and a 200 day simple moving average of $49.85.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on DRUG shares. Zacks Research lowered shares of Bright Minds Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 2nd. Chardan Capital raised shares of Bright Minds Biosciences to a “strong-buy” rating in a research note on Wednesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $85.00 target price on shares of Bright Minds Biosciences in a report on Monday, September 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Bright Minds Biosciences in a research note on Monday, December 1st. Finally, Wall Street Zen raised Bright Minds Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Bright Minds Biosciences presently has an average rating of “Buy” and an average target price of $82.50.

Hedge Funds Weigh In On Bright Minds Biosciences

Several large investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP bought a new position in Bright Minds Biosciences during the third quarter valued at $650,000. Vanguard Group Inc. raised its position in shares of Bright Minds Biosciences by 41.0% during the 3rd quarter. Vanguard Group Inc. now owns 45,103 shares of the company’s stock valued at $2,736,000 after buying an additional 13,120 shares in the last quarter. Geode Capital Management LLC bought a new position in shares of Bright Minds Biosciences in the 2nd quarter valued at about $1,502,000. Goldman Sachs Group Inc. purchased a new position in Bright Minds Biosciences in the first quarter worth about $802,000. Finally, Millennium Management LLC increased its stake in Bright Minds Biosciences by 376.9% during the first quarter. Millennium Management LLC now owns 192,557 shares of the company’s stock worth $6,946,000 after acquiring an additional 152,178 shares during the last quarter. Hedge funds and other institutional investors own 40.52% of the company’s stock.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.